FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557183774> ?p ?o ?g. }

• W2557183774 endingPage "196" @default.
• W2557183774 startingPage "191" @default.
• W2557183774 abstract "Purpose. To comparatively evaluate the antihypertensive efficacy and tolerability of preservative-free Tafluprost 0,0015% and Latanoprost 0,005% with preservative (0.02% BACH) in patients with initial and advanced stages of POAG. patients and methods. 63 patients (83 eyes) with primary open-angle glaucoma, aged from 56 to 75 years. 21 Men, 42 women. Patients were randomized intwo groups. The first group consisted of 32 patients (38 eyes), they received Latanoprost 0,005% (Prolatan®, “Sentiss Pharma”,) 1 drop once daily in the evening. The second group consisted of 31 (45 eyes) of patients treated with Tafluprost 0,0015% (Taflotan® JSC, “Santen”, Finland) 1 drop once daily in the evening. The follow-up period was 3 months. results. All patients had received reliable decrease in the true IOP: on monotherapy with Prolatan® on average by 27.8% (from 22.5±0,14 to 17.6±0,14 mm Hg.St.) in the first month, 26.4% (22,5±0,14 to 17.8±0,14 mm Hg.St) in third. In patients treated with Taflotan, reduction of IOP was approximately on the same level: 29.7 % in a month, 26.8 % in three months. The study of perimetry showed significant improvement of the MD index by 17.4% in the first group and 20% in the second, index, PSD, respectively, 10.7% and 11.9%. Improved parameters as a result of reduction IOP of optic nerve head were in both groups. But a significant decrease in the volume and area of excavation, respectively, 8.4% and 24.4% as well asincreasing the area of the disc rim band by 20.8% were observed only in the first group (instillation Prolatan®). Side effects were registered in 6 patients from the first group and 7 patients from the second group. One patient had several side effects. A mild hyperemia was identified in 3 patients of the first group and 2 from the second group at 4 week, in 5 out of first and 4 from second 8 week. Flushing medium degree was observed in 2 patients of the first group and 3 of the second group at 4 week. Conclusion. Thus, a comparative study has shown that the antihypertensive efficacy of the drug Prolatan comparable with the value of the drug Taflotan. According to optical coherence tomography as a result of treatment significantly decreased the volume, the area of excavation and the increased area of the disc rim of the shoulder in patients of the first group and was not observed in patients of the second group, which may indirectly indicate possible neuroprotective properties of the drug Prolatan. Side effects were registered in both groups, mostly of local character in the form of hyperemia of mild and moderate, increased pigmentation and growth of eyelashes. Patients in both groups noted the complete absence of burning, discomfort, foreign body in the administration of the drugs for a long period of time, with no cases of general disorder." @default.
• W2557183774 created "2016-11-30" @default.
• W2557183774 creator A5067131234 @default.
• W2557183774 date "2016-01-01" @default.
• W2557183774 modified "2023-10-14" @default.
• W2557183774 title "COMPARATIVE EVALUATION OF ANTIHYPERTENSIVE DRUG’S EFFICACY IN PATIENTS WITH PRIMARY GLAUCOMA AT EARLY AND ADVANCED STAGES" @default.
• W2557183774 doi "https://doi.org/10.18008/1816-5095-2016-3-191-196" @default.
• W2557183774 hasPublicationYear "2016" @default.
• W2557183774 type Work @default.
• W2557183774 sameAs 2557183774 @default.
• W2557183774 citedByCount "0" @default.
• W2557183774 crossrefType "journal-article" @default.
• W2557183774 hasAuthorship W2557183774A5067131234 @default.
• W2557183774 hasBestOaLocation W25571837741 @default.
• W2557183774 hasConcept C118487528 @default.
• W2557183774 hasConcept C121332964 @default.
• W2557183774 hasConcept C126322002 @default.
• W2557183774 hasConcept C1276947 @default.
• W2557183774 hasConcept C197934379 @default.
• W2557183774 hasConcept C2776476923 @default.
• W2557183774 hasConcept C2776740260 @default.
• W2557183774 hasConcept C2778375690 @default.
• W2557183774 hasConcept C2778527774 @default.
• W2557183774 hasConcept C2991803831 @default.
• W2557183774 hasConcept C71924100 @default.
• W2557183774 hasConceptScore W2557183774C118487528 @default.
• W2557183774 hasConceptScore W2557183774C121332964 @default.
• W2557183774 hasConceptScore W2557183774C126322002 @default.
• W2557183774 hasConceptScore W2557183774C1276947 @default.
• W2557183774 hasConceptScore W2557183774C197934379 @default.
• W2557183774 hasConceptScore W2557183774C2776476923 @default.
• W2557183774 hasConceptScore W2557183774C2776740260 @default.
• W2557183774 hasConceptScore W2557183774C2778375690 @default.
• W2557183774 hasConceptScore W2557183774C2778527774 @default.
• W2557183774 hasConceptScore W2557183774C2991803831 @default.
• W2557183774 hasConceptScore W2557183774C71924100 @default.
• W2557183774 hasIssue "3" @default.
• W2557183774 hasLocation W25571837741 @default.
• W2557183774 hasLocation W25571837742 @default.
• W2557183774 hasOpenAccess W2557183774 @default.
• W2557183774 hasPrimaryLocation W25571837741 @default.
• W2557183774 hasRelatedWork W1477166354 @default.
• W2557183774 hasRelatedWork W1966402177 @default.
• W2557183774 hasRelatedWork W2027788223 @default.
• W2557183774 hasRelatedWork W2162221629 @default.
• W2557183774 hasRelatedWork W2324477148 @default.
• W2557183774 hasRelatedWork W2586739120 @default.
• W2557183774 hasRelatedWork W2775350857 @default.
• W2557183774 hasRelatedWork W2886435389 @default.
• W2557183774 hasRelatedWork W2897540273 @default.
• W2557183774 hasRelatedWork W4309147582 @default.
• W2557183774 hasVolume "13" @default.
• W2557183774 isParatext "false" @default.
• W2557183774 isRetracted "false" @default.
• W2557183774 magId "2557183774" @default.
• W2557183774 workType "article" @default.